This data indicated a higher percentage of MDM2 amplification in LUAD patients with solid, micropapillary and invasive mucinous subtypes that are associated with increased aggressiveness and lower survival [12,13] across all subtypes with the highest in most invasive solid subtype, suggesting MDM2 gain is associated with more tumor invasiveness [14,15]. The gene discussed is MDM2; the disease is neoplasm.